Methylphenidate and Parkinson's Disease

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to determine if methylphenidate (MPD), a drug marketed in the U.S. to treat hyperactivity and narcolepsy, added to levodopa, will increase the beneficial effects of levodopa without bothersome side effects in people with Parkinson's disease (PD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• Idiopathic PD treated with levodopa and experiencing motor fluctuations

• At least 21 years of age

• Male or female.

Exclusion Criteria:

• Cardiovascular disease, psychosis, extreme anxiety, dementia and other unstable medical conditions.